First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial
05 juin 2024 08h30 HE
|
Imunon, Inc.
DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company...
IMUNON’s VP of R&D to Present at the Vaccines Summit-2023
14 nov. 2023 09h00 HE
|
Imunon, Inc.
Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON’s PlaCCine modality and its applicability to multiple pathogens LAWRENCEVILLE, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) --...